Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations

• Main Authors: Dan Xu (Author), Ankith Nair (Author), Charlie Sigston (Author), Chau Ho (Author), Jia Li (Author), Daya Yang (Author), Xinxue Liao (Author), Wei Chen (Author), Ming Kuang (Author), Yanbing Li (Author), Christopher Reid (Author), Haipeng Xiao (Author)
• Format: Book
• Published: Hindawi-Wiley, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been observed in several large cardiovascular outcome trials to significantly reduce the incidence of major cardiovascular event (MACE) with type 2 diabetic patients. The clinical trials of GLP-1 RAs, including lixisenatide, exenatide, lirag...